Australia's LTR Pharma rises on TGA nod for SPONTAN Phase II clinical study

Ltr Pharma

10/12/2025 03:40

** LTR Pharma LTP.AX rises as much as 7.5% to A$0.50, highest since November 27

** Biopharmaceutical firm gets regulatory clearance from Therapeutic Goods Administration for its SPONTAN Phase II clinical study

** Says study expected to generate prescribing insights for physicians treating older men

** About 478,000 shares traded, 1.9x the 30-day avg

** LTP last up 3.2%, trimming YTD losses to 40.7%

 (Reporting by Anjali Singh in Bengaluru)

 ((anjali.singh2@thomsonreuters.com;))